Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II

Diagnostic Pathology

Sverre H Torp¹  Stein Sundstrøm²  Rosilin K Varughese³  Tove Lind-Landström³ 

[1]Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim, NO-7006, Norway

[2]Department of Oncology, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway

[3]Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

关键词: Survival;    Prognosis;    Ki67/MIB-1;    Immunohistochemistry;    Gliomas;    Diagnosis;    Brain tumours;   

Others  :  807133
DOI  :  10.1186/1746-1596-8-67

 received in 2013-03-14, accepted in 2013-04-19,  发布年份 2013

【 摘 要 】

Background

The WHO classification system for astrocytomas is not considered optimal, mainly because of the subjective assessment of the histopathological features. Few prognostic variables have been found that stratify the risk of clinical progression in patients with grade II astrocytoma. For that reason there is a continuous search for biomarkers that can improve the histopathological diagnosis and prognostication of these tumours.

Aim

This study was designed to investigate the prognostic significance of the proliferative marker Mcm2 (minichromosome maintenance protein 2) in diffuse astrocytomas WHO grade II and correlate the findings with histopathology, mitoses, and Ki67/MIB-1 immunostaining.

Method

61 patients with histologically verified grade II astrocytoma (WHO 2007) were investigated. Paraffin sections were immunostained with anti-Mcm2, and the Mcm2 proliferative index (PI) was determined as the percentage of immunoreactive tumour cell nuclei.

Results

Mcm2 PI was not associated with any histopathological features but correlated significantly with mitotic count and Ki67/MIB-1 PI (p<0.05). In the survival analyses Mcm2 showed trends to poorer survival, however, statistical significance was not achieved in the univariate analyses (p>0.05).

Conclusions

In our hands Mcm2 immunostaining has no advantage over Ki67/MIB-1 in the evaluation of grade II astrocytomas. Larger studies are needed to fully clarify the prognostic role of this biomarker.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1715002791944037 webcite

【 授权许可】

   
2013 Lind-Landström et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: WHO Classification of Tumours of the Central Nervous System. 4th edition. IARC: Lyon; 2007.
• [2]Jansen M, Yip S, Louis DN: Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 2010, 9:717-726.
• [3]Gomori E, Pal J, Kovacs B, Doczi T: Concurrent hypermethylation of DNMT1. MGMT and EGFR genes in progression of gliomas. Diagn Pathol 2012, 7:8. BioMed Central Full Text
• [4]Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH: Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Diagn Pathol 2010, 5:18. BioMed Central Full Text
• [5]Habberstad AH, Gulati S, Torp SH: Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas–an immunohistochemical study. Diagn Pathol 2011, 6:43. BioMed Central Full Text
• [6]Cavalla P, Schiffer D: Cell cycle and proliferation markers in neuroepithelial tumors. Anticancer Res 1997, 17:4135-4143.
• [7]Prayson RA: Cell proliferation and tumors of the central nervous system. Part 1: Evaluation of mitotic activity. J Neuropathol Exp Neurol 2002, 61:501-509.
• [8]Prayson RA: Cell proliferation and tumors of the central nervous system, part II: radiolabeling, cytometric, and immunohistochemical techniques. J Neuropathol Exp Neurol 2002, 61:663-672.
• [9]Johannessen AL, Torp SH: The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 2006, 12:143-147.
• [10]WHO: Classification Tumours of the Nervous System. 4th edition. Lyon: IARC; 2007.
• [11]Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992, 168:357-363.
• [12]Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET: Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 1997, 56:857-865.
• [13]Prayson RA: The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv Anat Pathol 2005, 12:144-148.
• [14]Taran K, Sitkiewicz A, Andrzejewska E, Kobos J: Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour. Pol J Pathol 2011, 62:84-88.
• [15]Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, Coleman N: Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999, 5:2121-2132.
• [16]Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH: Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 2001, 27:305-313.
• [17]Hunt DP, Freeman A, Morris LS, Burnet NG, Bird K, Davies TW, Laskey RA, Coleman N: Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein. Br J Neurosurg 2002, 16:10-15.
• [18]Lind-Landstrom T, Habberstad AH, Torp SH: Proliferative activity and histopathological features in diffuse grade II astrocytomas. APMIS 2012, 120:640-647.
• [19]Lind-Landstrom T, Habberstad AH, Sundstrom S, Torp SH: Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol 2012, 5:152-158.
• [20]Margraf LR, Gargan L, Butt Y, Raghunathan N, Bowers DC: Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas–an assessment of 3 new variables in predicting clinical outcome. Neuro Oncol 2011, 13:767-774.
• [21]Wojnar A, Kobierzycki C, Krolicka A, Pula B, Podhorska-Okolow M, Dziegiel P: Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers. Folia Histochem Cytobiol 2010, 48:442-446.
• [22]Werynska B, Pula B, Muszczynska-Bernhard B, Piotrowska A, Jethon A, Podhorska-Okolow M, Dziegiel P, Jankowska R: Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Anticancer Res 2011, 31:2833-2839.
• [23]Hanna-Morris A, Badvie S, Cohen P, McCullough T, Andreyev HJ, Allen-Mersh TG: Minichromosome maintenance protein 2 (MCM2) is a stronger discriminator of increased proliferation in mucosa adjacent to colorectal cancer than Ki-67. J Clin Pathol 2009, 62:325-330.
• [24]Seidal T, Balaton AJ, Battifora H: Interpretation and quantification of immunostains. Am J Surg Pathol 2001, 25:1204-1207.
• [25]Torres-Rendon A, Roy S, Craig GT, Speight PM: Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer 2009, 100:1128-1134.
• [26]Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715.
• [27]Brat DJ, Prayson RA, Ryken TC, Olson JJ: Diagnosis of malignant glioma: role of neuropathology. J Neurooncol 2008, 89:287-311.
• [28]Alison MR, Hunt T, Forbes SJ: Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Gut 2002, 50:290-291.
• [29]Hall PA, Coates PJ: Assessment of cell proliferation in pathology–what next? Histopathology 1995, 26:105-112.
• [30]Schiffer D, Cavalla P, Chio A, Richiardi P, Giordana MT: Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol 1997, 34:31-35.